Placeholder Banner

BIO Statement for the Record: House Ways & Means Subcommittee on Health hearing on Examining Policies that Inhibit Innovation and Patient Access

May 10, 2023

BIO’s comments focus on two areas that threaten patient access to innovative medicines in Medicare: (1) the anti-innovation policies enacted as part of the Inflation Reduction Act, and (2) government policies that that are blocking patient access to new FDA-approved treatments.


Download Full Comments Below
BIO Statement for W+M Health Subcom
Discover More
In these comments, BIO addresses FDA’s four specific topic areas of consideration as the agency develops its draft guidance per PDUFA VII.
BIO joined with more than 40 groups in calling on Congress to set 2024 funding for the U.S. Codex Office at or above the 2023 level. 
BIO’s comments support accelerated approval as an important regulatory pathway that allows patients with serious and life-threatening illnesses such as cancer to have earlier access to promising therapies.